Eli Lilly's Retatrutide Cuts Blood Sugar & Weight in Trial
Eli Lilly's triple-G drug retatrutide showed significant HbA1C and weight reductions in type 2 diabetes patients at 40 weeks in a 2026 late-stage trial.
2 articles tagged "type 2 diabetes"
Eli Lilly's triple-G drug retatrutide showed significant HbA1C and weight reductions in type 2 diabetes patients at 40 weeks in a 2026 late-stage trial.
A recent Nature Medicine study demonstrates that somatic loss of the Y chromosome significantly increases type 2 diabetes risk in East Asian men, particularly those with low polygenic risk scores, with direct evidence of Y chromosome loss in pancreatic β-cells.